Sign In
Buy TMDX
$76.51
+0.380 (+0.499%)
At Close: Jul 31, 2026
TransMedics to Present at Upcoming September Investor Conferences
04:05pm, Monday, 25'th Aug 2025
ANDOVER, Mass. , Aug. 25, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
TransMedics: CEO Is Buying Shares Ahead Of A Potentially Concerning Q3
03:36am, Monday, 25'th Aug 2025
TransMedics delivered another strong beat-and-raise quarter, but Q3 faces a likely seasonal slowdown that could disappoint optimistic investors. The long-term thesis remains robust: best-in-class pres
Here's Why TransMedics (TMDX) is a Strong Momentum Stock
10:50am, Friday, 22'nd Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why TransMedics (TMDX) is a Strong Growth Stock
10:46am, Wednesday, 20'th Aug 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
TransMedics (TMDX) Recently Broke Out Above the 50-Day Moving Average
10:31am, Tuesday, 12'th Aug 2025
TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX broke out above the 50-day moving average, suggesting
Why TransMedics (TMDX) is a Top Momentum Stock for the Long-Term
10:51am, Wednesday, 06'th Aug 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why TransMedics (TMDX) is a Top Growth Stock for the Long-Term
10:45am, Monday, 04'th Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial
08:00am, Monday, 04'th Aug 2025
ANDOVER, Mass. , Aug. 4, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Friday, 01'st Aug 2025
ANDOVER, Mass. , Aug. 1, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
01:11pm, Friday, 01'st Aug 2025
TransMedics stock jumps 10.5% as Q2 EPS beats by 91.7%, revenue rises 37.7%, and operating margin expands 1230 basis points.
TransMedics: Continued Strength Suggests Further Upside
06:25am, Friday, 01'st Aug 2025
TransMedics delivered strong Q2 results, with revenue growth remaining robust and margins improving sharply. While there are concerns around the regulatory environment, competition, and seasonality, T
Why TransMedics Stock Is Skyrocketing Today
01:16pm, Thursday, 31'st Jul 2025
Shares of leading organ transplant technology company TransMedics (TMDX 12.66%) rose 15% as of noon ET on Thursday, according to data provided by S&P Global Market Intelligence.
TransMedics (TMDX) Q2 Revenue Jumps 38%
05:16am, Thursday, 31'st Jul 2025
TransMedics Group (TMDX 2.92%), a leader in organ transplant technology, released its second quarter 2025 earnings on July 30, 2025. The company topped Wall Street expectations, posting GAAP revenue o
TransMedics Group, Inc. (TMDX) Q2 2025 Earnings Call Transcript
12:28am, Thursday, 31'st Jul 2025
TransMedics Group, Inc. (NASDAQ:TMDX ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Tr
TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say
08:01pm, Wednesday, 30'th Jul 2025
The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estim
